“Achieving CFDA clearance in China is a testament to the attention to detail and quality that we place on our manufacturing processes, and opens the door for our entire range of flow cytometry solutions to be approved for clinical use in countries worldwide,” noted Dr. Wenbin Jiang, CEO of Cytek Biosciences.
Manufactured at Cytek’s facility in Wuxi, China, the DxP Athena incorporates Cytek's proven DxP technology, which gives scientists the ability to resolve dim populations in a multicolor format. The Athena is set apart from Cytek’s flagship Aurora and Northern Lights spectral flow cytometers by its use of traditional flow technology. However, like all other Cytek flow cytometer systems, the DxP Athena system is compact, hands-on, affordable, and easy-to-use. Assays require only micro-volumes of cells and reagents, and generate minimal waste.
Additionally, Cytek’s QbSure QC product has been approved by the CFDA for use with the DxP Athena. Included with the DxP Athena are Cytek’s validation beads and QbSure QC software, which ensure optimal daily instrument performance.
As the next step in its mission to make massively multiparametric flow cytometry accessible to a larger number of researchers, Cytek anticipates CFDA approval for its spectral flow cytometry solutions in 2019.
Cytek Biosciences Inc. is a flow cytometry solution provider that develops compact, affordable instruments with high multiplexing capability and a wide range of services to support scientists and clinicians. Cytek is headquartered in Fremont, Calif., with branch offices and distribution channels across the globe.